Human Dental Pulp Stem Cell therapy - Cellavita
Alternative Names: HDPSC - CellavitaLatest Information Update: 16 Jan 2024
At a glance
- Originator Cellavita
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Huntington's disease
Most Recent Events
- 31 Oct 2023 Cellavita plans a phase III STAR trial for Hunginton's disease (IV) in June 2024